VISEN Pharmaceuticals (HKG:2561)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
32.56
+1.06 (3.37%)
At close: Mar 10, 2026
Market Cap3.31B
Revenue (ttm)921.55K
Net Income-237.56M
EPS-2.45
Shares Out105.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,600
Average Volume8,700
Open31.50
Previous Close31.50
Day's Range31.50 - 32.98
52-Week Range29.06 - 69.15
Betan/a
RSI46.27
Earnings DateMar 12, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy f... [Read more]

Sector Healthcare
Founded 2018
Employees 54
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2561
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements